Vir Biotechnology, Inc.
VIR evidence brief
What we can confirm
- BioSniper Score:
- 7.7 / 10
- Market Cap:
- $1.83B
- Lead Asset:
- elebsiran (Phase 3)
What it means
What to watch
Prepared research question
What matters most for VIR—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · VIR
Vir Biotechnology, Inc. (VIR) is a publicly traded biopharmaceutical company developing therapies for infectious diseases (hepatitis B and delta, HIV) and oncology (prostate cancer, HER2-expressing cancers, solid tumors), with its lead hepatitis delta program in Phase 3 and multiple oncology candidates in Phase 1/2.
Key risk: Early-stage oncology pipeline
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 6 pipeline candidates · 14 clinical trials for Vir Biotechnology, Inc..
Vir Biotechnology, Inc. (VIR) is a publicly traded biopharmaceutical company developing therapies for infectious diseases (hepatitis B and delta, HIV) and oncology (prostate cancer, HER2-expressing cancers, solid tumors), with its lead hepatitis delta program in Phase 3 and multiple oncology candidates in Phase 1/2.
- Cash & equivalents of $278.7M as of 2026-06-30 [sec].
- Total revenue of $238.9M and net income of $80.1M as of 2026-06-30 [sec].
- Lead hepatitis delta combination (tobevibart + elebsiran) in Phase 3 with Breakthrough Therapy and Fast Track designations [pipeline].
- Oncology pipeline includes VIR-5500 (Phase 1, PSMA-targeting T-cell engager for mCRPC), VIR-5818 (Phase 2, HER2-targeted T-cell engager), and VIR-5525 (Phase 1, EGFR-targeted T-cell engager) [pipeline].
- Partnerships with Sanofi (oncology and infectious disease rights) and Norgine (Europe/Australia/New Zealand rights for tobevibart) [pipeline].
What works
- Strong cash position of $278.7M as of 2026-06-30 provides runway into 2028 [sec][news].
- Lead hepatitis delta program has regulatory momentum with Breakthrough Therapy and Fast Track status [pipeline].
- Multiple near-term catalysts in 2026 across hepatitis and oncology programs [news].
What to weigh
- Oncology candidates are early-stage (Phase 1/2) and face crowded competitive landscapes (e.g., VIR-5500 has 48 competitors, VIR-5525 has 163) [pipeline].
- HIV program is preclinical and has no disclosed clinical timeline [pipeline].
- Revenue of $238.9M as of 2026-06-30 is modest relative to shareholders' equity of $982.5M, suggesting limited product revenue [sec].
From the filings
Quoted directly from source documents.
Risks & what to watch (3)›
Key risks
- Early-stage oncology pipeline — All oncology candidates are Phase 1/2; VIR-5500 faces 48 competitors, VIR-5525 faces 163 [pipeline].
- Preclinical HIV program — HIV bnAb program is preclinical with no disclosed clinical timeline [pipeline].
- Modest product revenue — Revenue of $238.9M as of 2026-06-30 is low relative to equity of $982.5M [sec].
What to watch
- Phase 2 SOLSTICE data for tobevibart + elebsiran in chronic hepatitis delta at upcoming EASL meeting [news·2026-05-18].
- VIR-5500 Phase 1 expansion cohort data and ASCO GU update in 2026 [news·2026-02-05].
- VIR-5818 Phase 2 update expected H2 2026 [news·2026-02-05].
- ECLIPSE 1 hepatitis delta readout in Q4 2026 [news·2026-02-05].
Sources: Catalysts · News · Pipeline · Generated October 3, 2026 · How we verify sources →
Run Vir Biotechnology, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Vir Biotechnology, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.24 · 1% dilution
Lead: Phase 3
6 candidates
No upcoming catalysts tracked
0 buys · 3 sells (180d)
Pipeline
Regulatory
Financials
Short Interest
as of May 22, 2026- % of float
- 9.7%
- Days to cover
- 9.0
- Shares short
- 16,117,209
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
VIR short interestGovernance
Frequently asked questions
What is the AI investment thesis for Vir Biotechnology, Inc.?
Vir Biotechnology, Inc. (VIR) is a publicly traded biopharmaceutical company developing therapies for infectious diseases (hepatitis B and delta, HIV) and oncology (prostate cancer, HER2-expressing cancers, solid tumors), with its lead hepatitis delta program in Phase 3 and multiple oncology candidates in Phase 1/2.
What is Vir Biotechnology, Inc.'s lead drug candidate?
Vir Biotechnology, Inc.'s most advanced tracked candidate is elebsiran (Phase 3) for Viral Hepatitis.
Who is the CEO of Vir Biotechnology, Inc.?
Dr. Marianne De Backer M.B.A., M.Sc., Ph.D. is the chief executive officer of Vir Biotechnology, Inc. (VIR).
Where is Vir Biotechnology, Inc. headquartered?
Vir Biotechnology, Inc. (VIR) is headquartered in San Francisco, CA, United States.
What therapeutic areas does Vir Biotechnology, Inc. focus on?
Vir Biotechnology, Inc. develops therapies across Oncology, Neurology, Infectious Disease, Gastroenterology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.